Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin.

Iwasaki Y, Shimada T, Kishimori T, Kato T, Koike J, Matsumoto T, Yagi T, Okada M

Diabetes research and clinical practice23 Dec 2025Cited by 2 (Europe PMC)

PMID41448390DOI10.1016/j.diabres.2025.113072PepBankPUB-41448390

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, tirzepatide was associated with a lower 1-year incidence of major adverse cardiovascular and limb events than sitagliptin (4.3% vs 6.1%; HR 0.70).
In plain wordsIn adults with type 2 diabetes, tirzepatide was linked to fewer major heart and limb events than sitagliptin.
Peptide
Tirzepatide
Outcome
DecreaseMACLE at 1 year
Study
n = 31,751
Comparator
Sitagliptin
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Hazard ratio
0.7 HR
MACLE, tirzepatide vs sitagliptin
Incidence tirzepatide
4.3%
1 year
Incidence sitagliptin
6.1%
1 year
Source sentences
Summary
At 1 year, the incidence of MACLE was lower with tirzepatide compared to that with sitagliptin (4.3 % vs. 6.1 %; hazard ratio (HR), 0.70; 95 % confidence interval (CI), 0.66-0.76; p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX global health research network to identify patients with type 2 diabetes (T2D) who initiated tirzepatide or sitagliptin between January 2022 and December 2023.
Summary · context
After matching, 31,751 patients per group were analyzed.
Report a problemFND-4144839001
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, tirzepatide was associated with a lower risk of major adverse cardiovascular events than sitagliptin (HR 0.71).
In plain wordsIn adults with type 2 diabetes, tirzepatide was linked to fewer major heart events than sitagliptin.
Peptide
Tirzepatide
Outcome
DecreaseMACE
Study
n = 31,751
Comparator
Sitagliptin
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Hazard ratio
0.71 HR
MACE
Source sentences
Summary
Tirzepatide was also associated with a reduced risk of MACE (HR, 0.71; 95 % CI, 0.66-0.76), MALE (HR, 0.39; 95 % CI, 0.34-0.46), and major lower extremity amputation (HR, 0.61; 95 % CI, 0.44-0.84).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX global health research network to identify patients with type 2 diabetes (T2D) who initiated tirzepatide or sitagliptin between January 2022 and December 2023.
Summary · context
After matching, 31,751 patients per group were analyzed.
Report a problemFND-4144839002
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, tirzepatide was associated with a lower risk of major adverse limb events than sitagliptin (HR 0.39).
In plain wordsIn adults with type 2 diabetes, tirzepatide was linked to fewer major limb events than sitagliptin.
Peptide
Tirzepatide
Outcome
DecreaseMALE
Study
n = 31,751
Comparator
Sitagliptin
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Hazard ratio
0.39 HR
MALE
Source sentences
Summary
Tirzepatide was also associated with a reduced risk of MACE (HR, 0.71; 95 % CI, 0.66-0.76), MALE (HR, 0.39; 95 % CI, 0.34-0.46), and major lower extremity amputation (HR, 0.61; 95 % CI, 0.44-0.84).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX global health research network to identify patients with type 2 diabetes (T2D) who initiated tirzepatide or sitagliptin between January 2022 and December 2023.
Summary · context
After matching, 31,751 patients per group were analyzed.
Report a problemFND-4144839003
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, tirzepatide was associated with a lower risk of major lower extremity amputation than sitagliptin (HR 0.61).
In plain wordsIn adults with type 2 diabetes, tirzepatide was linked to fewer major leg amputations than sitagliptin.
Peptide
Tirzepatide
Outcome
DecreaseMajor lower extremity amputation
Study
n = 31,751
Comparator
Sitagliptin
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Hazard ratio
0.61 HR
major lower extremity amputation
Source sentences
Summary
Tirzepatide was also associated with a reduced risk of MACE (HR, 0.71; 95 % CI, 0.66-0.76), MALE (HR, 0.39; 95 % CI, 0.34-0.46), and major lower extremity amputation (HR, 0.61; 95 % CI, 0.44-0.84).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX global health research network to identify patients with type 2 diabetes (T2D) who initiated tirzepatide or sitagliptin between January 2022 and December 2023.
Summary · context
After matching, 31,751 patients per group were analyzed.
Report a problemFND-4144839004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.